Production (Stage)
Krystal Biotech, Inc.
KRYS
$136.94
$4.323.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 116.86% | 715.58% | 275.67% | 175.45% | 142.25% |
| Total Depreciation and Amortization | -25.95% | -33.19% | -18.81% | -9.56% | -2.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 175.51% | 168.92% | 163.56% | -276.51% | -290.36% |
| Change in Net Operating Assets | 4.23% | 62.47% | -169.34% | -1,807.94% | -163.95% |
| Cash from Operations | 396.20% | 238.98% | 160.97% | 83.65% | 57.96% |
| Capital Expenditure | -19.59% | 64.08% | 65.17% | 78.07% | 81.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -366.63% | -2,761.78% | -3,164.04% | -803.53% | -191.80% |
| Cash from Investing | -462.05% | -297.78% | -202.55% | 253.65% | 197.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.76% | -84.08% | -84.02% | -77.88% | 470.02% |
| Repurchase of Common Stock | -158.60% | -619.09% | -619.09% | -619.09% | -619.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.13% | -86.68% | -86.61% | -80.60% | 467.03% |
| Foreign Exchange rate Adjustments | -807.46% | -193.59% | 92.98% | -302.90% | 187.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.02% | -106.85% | -99.61% | 22.32% | 269.78% |